In this interview we talk with bestselling author, Michael Pollan, who is also one of the founding members of the UC Berkeley Center for the Science of Psychedelics.

In this webinar we talk to Dr. Matthew Johnson, a Professor of Psychiatry & Behavioral Sciences at Johns Hopkins University School of Medicine and Associate Center Director of the Center for Psychedelics and Consciousness Research.

In this interview we’ll talk with Dr. Julie Holland to discuss her new book, Good Chemistry: The Science of Connection, from Soul to Psychedelics. This book explores connection — why we need it, how we’ve lost it, and how we might find it again as well as how psychedelics could be used in psychiatry to make treatments more efficient and effective.

In this interview we’ll talk with Rachel Yehuda PhD, about trauma in the children of Holocaust survivors and the potential of psychedelic-assisted therapies.

In this interview we’ll talk with Christian Angermeyer (Founder, ATAI Life Sciences) about psychedelic-assisted therapies. ATAI’s focus is on developing innovative solutions for the more than 300 million people who suffer from depression, anxiety, and addiction, especially by bringing back formerly vilified drugs like psychedelics into the legal realm.

In this interview we’ll talk with Dr. Robin Carhart Harris. Robin has designed human brain imaging studies with LSD, psilocybin, MDMA and DMT, a clinical trial of psilocybin for treatment-resistant depression, an ongoing trial comparing psilocybin with escitalopram for major depressive disorder and a multimodal imaging study in healthy volunteers receiving psilocybin for the first time.

In this interview we’ll talk with Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is the leading non-profit research and educational organization developing legal medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana primarily as prescription medicines.

In this interview we’ll talk with George Goldsmith, Executive Chairman, CEO and Co-Founder of COMPASS Pathways (compasspathways.com). Founded in 2016, Compass is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD).